120 related articles for article (PubMed ID: 6226856)
21. A phase II study of chlorozotocin in metastatic malignant melanoma.
Hoth DF; Schein PS; Winokur S; Woolley PV; Robichaud K; Binder RB; Smith FP
Cancer; 1980 Oct; 46(7):1544-7. PubMed ID: 6448088
[TBL] [Abstract][Full Text] [Related]
22. Chlorozotocin: phase II evaluation in patients with advanced sarcomas.
Sordillo PP; Magill GB; Gralla RJ
Cancer Treat Rep; 1981; 65(5-6):513-4. PubMed ID: 6453647
[No Abstract] [Full Text] [Related]
23. Pulmonary disease as a complication of chlorozotocin chemotherapy.
Ahlgren JD; Smith FP; Kerwin DM; Sikic BI; Weiner JH; Schein PS
Cancer Treat Rep; 1981; 65(3-4):223-9. PubMed ID: 6453644
[TBL] [Abstract][Full Text] [Related]
24. Phase I evaluation of chlorozotocin: single dose every six weeks.
Taylor S; Belt RJ; Haas CD; Stephens RL; Hoogstraten B
Cancer; 1980 Dec; 46(11):2365-8. PubMed ID: 6449279
[TBL] [Abstract][Full Text] [Related]
25. Clinical trial of chlorozotocin, DTIC, and dactinomycin in metastatic malignant melanoma.
Samson MK; Baker LH; Cummings G; Talley RW; McDonald B; Bhathena DB
Cancer Treat Rep; 1982 Feb; 66(2):371-3. PubMed ID: 6459845
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of chlorozotocin in malignant melanoma, breast cancer, and other solid tumors.
Silver BA; Barlock AL; Lippman ME; Anderson T; Fisher RI
Cancer Treat Rep; 1982 May; 66(5):1229-30. PubMed ID: 6211231
[TBL] [Abstract][Full Text] [Related]
27. Cholestatic jaundice associated with chlorozotocin.
Belt RJ; McGregor D; Haas CD; Bhatia PS
Cancer Treat Rep; 1980; 64(12):1235-9. PubMed ID: 6451288
[TBL] [Abstract][Full Text] [Related]
28. Chlorozotocin: phase II evaluation in patients with myeloma.
Cornell CJ; Pajak TF; McIntyre OR
Cancer Treat Rep; 1984 Apr; 68(4):685-6. PubMed ID: 6231990
[No Abstract] [Full Text] [Related]
29. The effect of sequential addition of the nitrosourea, chlorozotocin, to the FAM combination in advanced gastric cancer.
Gisselbrecht C; Smith FP; MacDonald JS; Korsmeyer SJ; Boiron M; Woolley PV; Schein PS
Cancer; 1983 May; 51(10):1792-4. PubMed ID: 6219735
[TBL] [Abstract][Full Text] [Related]
30. Chlorozotocin, 2-(3-(2-chloroethyl)-3-nitrosoureido)-D-glucopyranose, an antitumor agent with modified bone marrow toxicity.
Anderson T; McMenamin MG; Schein PS
Cancer Res; 1975 Mar; 35(3):761-5. PubMed ID: 123170
[TBL] [Abstract][Full Text] [Related]
31. Phase II study of maytansine and chlorozotocin in patients with disseminated malignant melanoma.
Ahmann DL; Frytak S; Kvols LK; Hahn RG; Edmonson JH; Bisel HF; Creagan ET
Cancer Treat Rep; 1980; 64(4-5):721-3. PubMed ID: 6448689
[No Abstract] [Full Text] [Related]
32. Phase II evaluation of chlorozotocin in advanced bronchogenic carcinoma.
Creagan ET; Eagan RT; Fleming TR; Frytak S; Kvols LK; Ingle JN
Cancer Treat Rep; 1979; 63(11-12):2105-6. PubMed ID: 230898
[No Abstract] [Full Text] [Related]
33. Antitumor activity of chlorozotocin (NSC-178748).
Ungerleider RS
Cancer Treat Rev; 1980 Dec; 7(4):191-5. PubMed ID: 6452199
[No Abstract] [Full Text] [Related]
34. Preclinical and clinical studies on chlorozotocin, a new nitrosourea with decreased bone marrow toxicity.
Macdonald JS; Hoth D; Schein PS
Recent Results Cancer Res; 1980; 70():83-9. PubMed ID: 6444466
[TBL] [Abstract][Full Text] [Related]
35. Chlorozotocin (DCNU)--induced pulmonary toxicity.
Sordillo EM; Sordillo PP; Stover D; Magill GB
Cancer Clin Trials; 1981; 4(4):397-9. PubMed ID: 6459189
[TBL] [Abstract][Full Text] [Related]
36. Phase I trial of chlorozotocin: attempted amelioration of myelotoxicity by glucose administration.
Panasci L; Comis R; Ginsberg S; Kohn L; Fitzpatrick A; Rubert M; Scalzo T
Cancer Treat Rep; 1981; 65(7-8):647-50. PubMed ID: 6454483
[TBL] [Abstract][Full Text] [Related]
37. Carcinogenic activity in Sprague-Dawley rats of 2-[3-(2-chloroethyl)-3-nitrosoureido]-D-gluco-pyranose (chlorozotocin).
Habs M; Eisenbrand G; Schmähl D
Cancer Lett; 1979 Dec; 8(2):133-7. PubMed ID: 162366
[TBL] [Abstract][Full Text] [Related]
38. Phase II evaluation of chlorozotocin in patients with renal cell carcinoma.
Gralla RJ; Yagoda A
Cancer Treat Rep; 1979 Jun; 63(6):1007-8. PubMed ID: 157222
[No Abstract] [Full Text] [Related]
39. Phase II evaluation of chlorozotocin in patients with malignant melanoma.
Houghton AN; Camacho FJ; Gralla RJ; Wittes R
Cancer Treat Rep; 1981; 65(7-8):705-6. PubMed ID: 6454487
[No Abstract] [Full Text] [Related]
40. Phase II evaluation of chlorozotocin in patients with non-small cell carcinoma of the lung.
Casper ES; Gralla RJ
Cancer Treat Rep; 1979 Apr; 63(4):549-50. PubMed ID: 156068
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
